Provectus Biopharmaceuticals, Inc. (PVCT)

0,1470 +0,0070 (+5,00 %) À la clôture : 03:04PM EDT

Provectus Biopharmaceuticals, Inc.

800 South Gay Street
Suite 1610
Knoxville, TN 37929
United States
866 594 5999
https://www.provectusbio.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 4

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Edward V. Pershing CPA	CEO & Chairman of Board	75k	S.O.	1953
Mr. Dominic Rodrigues C.F.A.	President & Vice Chairman of the Board	75k	S.O.	1969
Dr. Eric A. Wachter Ph.D.	Co-Founder & CTO	253,25k	S.O.	1963
Ms. Heather Raines CPA	Chief Financial Officer	125k	S.O.	1967

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Provectus Biopharmaceuticals, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.